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Innate lymphoid cells (ILCs) have emerged recently as an important component of the immune system
and the cell type that regulates mucosal immune responses and tissue homeostasis. Group 2 ILCs (ILC2s),
a subset of ILCs, reside in various tissues and are characterized by their capacity to produce type 2 cy-
tokines and tissue growth factors. These ILC2s play an important role in allergic immune responses by
linking signals in the atmospheric environment to the immune system. Fungi are one of the major al-
lergens associated with human asthma, and animal and in vitro models using the fungal allergens have
provided signiﬁcant information toward our understanding of the mechanisms of allergic disease. In
mouse models of fungus-induced allergic airway inﬂammation, IL-33, IL-25, and TSLP are released by
airway epithelial cells. Lung ILC2s that respond to these cytokines quickly produce a large quantity of
type 2 cytokines, resulting in airway eosinophilia, mucus production, and airway hyperreactivity even in
the absence of adaptive immune cells. Evidence also suggests that ILC2s interact with conventional
immune cells, such as CD4þ T cells, and facilitate development of adaptive immune response and
persistent airway inﬂammation. ILC2s are also present in respiratory mucosa in humans. Further in-
vestigations into the biology of ILC2s and their roles in the pathophysiology of allergic diseases will
provide major conceptual advances in the ﬁeld and may provide useful information toward development
of new therapeutic strategies for patients.
Copyright © 2015, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
After the initial discovery and characterization of Th1- and Th2-
type CD4þ T cells approximately 25 years ago, T cells were thought
to play a central role in regulation of immune responses and
pathophysiology of diseases by producing a repertoire of cyto-
kines.1 However, the recent discovery of innate lymphoid cells
(ILCs) added another layer of complexity and provided a major shift
in this paradigm.2 ILCs have emerged as important effector cells of
the immune system that are involved in pathogen clearance,
lymphoid organogenesis, tissue remodeling and immune pathol-
ogy through production of distinct sets of cytokines and growth00 First Street SW, Rochester,
ety of Allergology.
rgology. Production and hosting by Elsefactors. These cells are derived from a common lymphoid progen-
itor, exhibit lymphoid morphology, but express no phenotypic
markers of conventional immune cells.3
ILCs have been categorized into three groups, including group 1
ILCs (ILC1s), group 2 ILCs (ILC2s), and group 3 ILCs (ILC3s), based on
their cytokine proﬁles and the transcription factors that are utilized
for their development and function.4 ILC1s comprise IFN-g-
secreting ILCs that use transcription factor T-bet for lineage
commitment. ILC2s comprise type 2 cytokine-producing ILCs that
require transcription factor GATA3 for their development and
function. ILC3s comprise IL-17- and/or IL-22-producing ILCs that
are dependent on transcription factor RORgt for lineage speciﬁca-
tion. This article will focus on ILC2s and discuss their roles in
allergic immune responses induced by fungal allergens. While
major progress has also been made regarding the roles for ILC2s in
viral infection and regulation of tissue homeostasis and meta-
bolism, they are discussed elsewhere in detail5 and will be
described only brieﬂy in this article.vier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
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Allergic asthma is generally mediated by dysregulated produc-
tion of Th2-type cytokines, such as IL-4, IL-5 and IL-13, although
other cell types, such as Th17 cells, have also been implicated.6 The
interactions between mucosal epithelia and innate and adaptive
immune cells were recently proposed as the underlying causes of
dysregulated production of Th2-type cytokines in allergic diseases.7
In particular, the epithelium-derived cytokines IL-33, IL-25, and
thymic stromal lymphopoietin (TSLP) have emerged as potential
links between environmental exposure to allergens and type 2
immune responses.8e11 For example, intraperitoneal injection of IL-
33 in mice increases serum levels of IgE and Th2 cytokines and
promotes airway eosinophilia and mucosal hyperplasia.12,13 Inha-
lation of IL-33 induces type 2 lung inﬂammation even in T cell- and
B cell-deﬁcient animals.14 TSLP activates DCs to polarize naïve T
cells towards the pro-inﬂammatory Th2 cells that produce IL-4, IL-
5, and IL-13 as well as TNF-a.15e17 Mice expressing TSLP in the lungs
develop spontaneous airway inﬂammation with characteristics
similar to human asthma.18
While a number of environmental factors are associated with
asthma and allergic diseases, allergen exposure likely plays a key
role in triggering and exacerbating asthma and allergy symptoms.19
In particular, exposure to airborne allergens derived from animals,
arthropods, and molds is considered to be an important risk
factor.20e22 In humans, an association between fungal exposure, in
particular to Alternaria and Aspergillus, and asthma is recognized
clinically and epidemiologically.23,24 Furthermore, severe asthma
and life-threatening acute exacerbations of asthma have also been
associated with increased airborne exposure to Alternaria.25e27
However, the molecular mechanisms involved in fungal exposure
and development of allergic immune responses are not well un-
derstood. Fungi secrete or contain numerous biologically active
substances, including chitin,28 b-glucan29 and proteases.30 Fungi
likely contribute to the majority of protease activity in house dust
samples.31 Certain fungal allergens are also proteases themselves,
including Asp f 5, f 6 and f 11 from Aspergillus,23 suggesting that
proteases may be a key link between fungal exposure and Th2-type
immune responses. Indeed, the protease activities produced by
fungi were sufﬁcient32,33 and necessary31 for induction of robust
allergic airway inﬂammation induced by fungal organisms. More-
over, a prototypic cysteine protease, such as papain, enhanced Th2-
type sensitization to bystander antigens.34
The conventional animal model of Th2-type immunity and “al-
lergy” involved intraperitoneal or subcutaneous sensitization of
mice with a model antigen ovalbumin (OVA) and an alum adjuvant,
followed by airway challenge with the OVA antigen. More recent
models used natural allergens, such as extracts of fungi and
authentic proteases, which were directly administered into the
airways of naïve and/or sensitized animals. These changes in the
experimental model systems as well as new discoveries in basic
science facilitated a major paradigm shift in our understanding of
the mechanisms of type 2 immune responses in the airways.
ILC2s
In the early 2000s, ILC2s were ﬁrst described in mice as non-B/
non-T cells that secrete IL-5 and IL-13 in response to IL-25.35,36
When mice were infected with the parasite Nippostrongylus brasi-
liensis or exposed to the fungus Aspergillus, increased expression of
IL-25 in the gut and lung was observed.35,36 A subsequent study
showed that these IL-25-responsive innate immune cells play
important roles in N. brasiliensis worm expulsion.37 In 2010, ILC2s
were isolated and characterized by several investigators, and they
were independently named as natural helper cells, nuocytes, andinnate helper 2 cells.38e40 Later a consensus report designated
them as group 2 ILCs (ILC2s).4
ILC2s arise from the common lymphoid progenitors (CLPs) in
the bone marrow and, like other ILCs, require the transcriptional
inhibitor Id2 for their development.38 Id2 inhibits the activity of the
E proteins, which are implicated in differentiation of B cells and T
cells.41 The transcription factor promyelocytic leukemia zinc ﬁnger
protein (PLZF) then mediates generation of an ILC precursor that
gives rises to ILC1, ILC2 and ILC3 but not conventional natural killer
(NK) cells.42 The transcription factor RORa is critical for further
development of ILC2s from the Id2-dependent ILC precursor.
Indeed, RORa-deﬁcient “Staggerer” mice, which carry a sponta-
neous mutation in the Rora gene, show severely impaired expan-
sion of ILC2s as well as cerebellar developmental defects43; the
other ILC subsets are not affected.44 Mice that have received bone
marrow from the “Staggerer”mice to circumvent their neurological
defects have been used as a model for ILC2-deﬁcient mice.45 While
GATA3 is required for the generation of the ILC precursor, it is also
required for maintenance and effector functions of ILC2s.46,47
ILC2s do not express conventional cell surface markers for T
cells, B cells, NK cells, myeloid cells, and DCs; thus, they are
designated lineage-negative (Lin). Mouse ILC2s express ST2 (IL-33
receptor), CD127 (IL-7R a-chain), ICOS, CD117 (c-kit), Thy1, IL-17RB
(IL-25 receptor), CD44 and CD25 (IL-2R a-chain); the expression
levels of these molecules varies depending on the anatomical
location and activation states of the cells.45 Mouse ILC2s are widely
distributed in the tissues, including fat-associated lymphoid clus-
ters (FALC), mesenteric and mediastinal lymph nodes, liver, spleen,
intestine, bone marrow, visceral adipose tissue and lung. Thus,
ILC2s appear to be critically positioned to maintain homeostasis by
responding rapidly to environmental cues, including metabolic
stress and nutrient intake, and poised to rapidly respond to damage
or stress in mucosal tissues. Functionally, ILC2s are considered to be
the counterpart of Th2-type CD4þ T cells. They characteristically
produce type 2 cytokines, such as IL-5, IL-13 and IL-9, as well as
certain growth factors, such as amphiregulin.48 Amphiregulin is a
member of the epidermal growth factor (EGF) family that promotes
epithelial cell growth.49
ILC2s normally reside in the lungs of naïve non-sensitized ani-
mals; these ILC2s are Lin and generally express various cell surface
markers, including CD117, CD122 (IL-2R b-chain), CD25, CD127,
Ly5.2, Thy1, Sca-1, ST2, CD69, CD9, CD38, MHC class II, CD44 and
ICOS.40,49e51 These cell markers have been used to identify and
isolate ILC2s among the Lin populations in the lung of naïve mice
(Fig. 1A). Importantly, lung ILC2s are present in Rag2/ mice (i.e.
deﬁcient in T cells) and ST2/ mice (i.e. deﬁcient in IL-33R), sug-
gesting that they do not require T cell help or IL-33 for their
development. In contrast, mice that are deﬁcient in IL-2 receptor
common g-chain (cg) or IL-7R a-chain lackmature ILC2s, consistent
with their dependency on IL-7 for their development. Lung ILC2s
are a rare cell population. In wild-type C57BL/6 mice, lung ILC2s
represent only 0.25e1% of total live cells in the lung. ILC2s are
located in collagen-rich regions close to the conﬂuence of medium-
sized blood vessels and airways, but not in alveolar areas of the
lung.52 Resting lung ILC2s show morphology similar to that of
resting lymphocytes, with no apparent intracellular granule
structures50 (Fig. 1B). Once they are activated by cytokines such as
IL-33, lung ILC2s increase in size and display pronounced endo-
plasmic reticulum and Golgi apparatus, suggesting that they are a
highly-activated cell type.
Human ILC2s are typically Lin, CD45þ, CD127þ, NKp44, CD25þ
and CD161þ.49,53e55 Distinct expression of two prototypic Th2-type
CD4þ T cell markers, namely chemoattractant receptor-
homologous molecule expressed on Th2 lymphocytes (CRTH2)
and IL-33 receptor ST2, is an unique feature of human ILC2s, and
Fig. 1. Lung ILC2s respond vigorously to IL-33 and produce a large quantity of IL-5 and IL-13 in vitro. (A) Gating strategy and identiﬁcation of ILC2s in lung single cell suspensions
from naïve BALB/c mice. (B) Morphology of lung ILC2s. Lung ILC2s were cultured with medium alone or IL-33 and examined under electron microscopy. Original magniﬁcations;
25,000 (medium alone, left) and 12,000 (IL-33, right).
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human ILCs.4 Human ILC2s are reportedly found in peripheral
blood, lung, BAL ﬂuid, nasal tissue, tonsil, gut and skin of normal
healthy individuals.
Regulation and functions of ILC2s
Resting lung ILC2s show high mRNA expression levels of Gata3,
Rora, Cd69, Il2ra, Il2rg, Il4ra, Il7r, Il17rb, Il1rl1, Il5, and Il13,40,51,52,56
consistent with transcriptional regulation of this cell type and its
effector function. ELISPOT assays revealed IL-5-producing lung
ILC2s when culturedwithout stimuli,52 suggesting constitutive (but
minimal) production of IL-5 by resting ILC2s. Importantly, this
constitutive expression of IL-5 by ILC2s may play an important role
in regulating eosinophil homeostasis in various organs.52,57
Growing evidence also links ILC2s with metabolic homeostasis,
obesity, and dietary stress.57e59 For example, deﬁciency of ILC2-
derived IL-5 and IL-13 led to increased adiposity and insulin
resistance.57 ILC2s also responded to the daily cycle of caloric
intake, resulting in cytokine expression associated with circadian
rhythms.52
ILC2s are activated by cytokines, such as IL-25, IL-33 and
TSLP,38e40,53,54 which are derived from epithelial cells and certain
immune cells. Activated lung ILC2s produce IL-4, IL-5, IL-9, IL-13
and GM-CSF.50,51,60 In particular, IL-5 and IL-13 protein are pro-
duced in large quantities by ILC2s, perhaps beyond the levels that
are produced by Th2-type CD4þ T cells, making these cells a unique
“factory” of cytokines.50 In in vitro culture systems, IL-33 activates
lung ILC2s probably more potently than IL-25 to produce IL-5 and
IL-13.50,51,61 In certain experiments, IL-25 and TSLP did not activate
lung ILC2s by themselves, but they synergistically enhanced cyto-
kine production by ILC2s in the presence of other cytokines, such as
IL-33.51 IL-25 and IL-33 also promote expansion and/ormigration of
lung ILC2s, as intraperitoneal or intranasal administration of IL-25
or IL-33 increased ILC2 cell numbers in lung tissues and draining
lymph nodes in vivo.40,62Lung ILC2 activities can also be regulated by IL-2-family cyto-
kines. In vitro, neither IL-2 nor IL-7 alone induces signiﬁcant IL-5
and IL-13 production by ILC2s. However, these two cytokines syn-
ergistically enhance IL-33- and IL-25-induced proliferation and
type 2 cytokine production by lung ILC2s.49e51 ILC2s were a
dominant source of IL-9 in mice exposed to the protease papain.60
IL-9 produced by ILC2s may have an autocrine positive feedback
effect on ILC2s since lung ILC2s cultured with IL-9 increased pro-
duction of type 2 cytokines.60,63 Finally, TL1A, a TNF superfamily
member, has also been reported to induce ILC2 cell expansion.64
Besides cytokines, lung ILC2s can be regulated by lipid media-
tors that are presumably generated during allergic inﬂammation by
mast cells, eosinophils, and other inﬂammatory cells.65 In vitro,
leukotriene D4 (LTD4) potently stimulates mouse lung ILC2s to
produce not only IL-5 and IL-13 but also a large amount of IL-4; IL-4
is not generally produced by ILC2s stimulated with IL-33.66 Intra-
nasal administration of LTD4 led to expansion of IL-5-producing
ILC2s in the lung in vivo. Furthermore, prostaglandin D2 (PGD2)
has also been shown to induce migration and functions of human
ILC2s through the CRTH2 receptor.67
Roles of ILC2s in innate type 2 responses to fungi
Initial studies on ILC2s demonstrated their roles in innate im-
munity against a variety of infectious organisms. For example, ILC2s
play critical roles in protective immunity against helminth
infection,38e40 in inﬂuenza-induced lung inﬂammation and airway
hyperreactivity (AHR),68 and in respiratory epithelial repair after
inﬂuenza infection.49 Therefore, it is reasonable to speculate that
ILC2s may involved in immune responses to fungal organisms or
their products.
To investigate this hypothesis, Alternaria extract was adminis-
tered once into the airways of naïve non-sensitized BALB/c mice.69
Th2 cytokine levels, including IL-5 and IL-13, were increased in as
early as 6 h after Alternaria exposure. Interestingly, within 1 h after
receiving Alternaria extract, IL-33 levels increased markedly in BAL
Fig. 2. Lung ILC2s mediate eosinophilic airway inﬂammation and pathology in mice
exposed to fungal allergen Alternaria. (A) ILC2s were isolated from the lungs of naïve
C57BL/6 mice, and they were adoptively transferred to naive Il7r/ mice, which are
deﬁcient in mature CD4þ T cells and ILCs. Mice were then exposed intranasally three
times to PBS or Alternaria extract over 6 days. Transferred ILC2s are identiﬁed as
LinCD25þCD44hi cells. The FACS plots were gated on Lin cells. (B) Cell number and
differentials in BAL ﬂuids were determined. (C) Representative histology (upper
panels: H&E staining, lower panels: PAS staining) of the mice as described in B.
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IL-5 and IL-13 in Alternariaeexposed mice was similar in Rag1/
and wild-type mice, suggesting that these type 2 cytokine re-
sponses are independent of adaptive immunity. In contrast, Alter-
naria-induced increases in IL-5 and IL-13 were abolished in mice
deﬁcient in IL-33 receptor ST2. Altogether, these ﬁndings suggested
that IL-33 likelymediates rapid production of Th2-type cytokines in
the airway mucosa through an innate mechanism(s). Robust
Alternaria-induced IL-33-dependent type 2 cytokine responses
were also observed in other studies.70,71 Interestingly, among the
various allergen extracts tested in these studies, only Alternaria
induced signiﬁcant IL-33 release into BAL ﬂuids, suggesting that
Alternaria has unique biological properties.
IL-33 was also involved in airway pathological changes in
response to Alternaria when non-sensitized naïve mice were
exposed repeatedly to Alternaria for a week.50 Mice exposed to
Alternaria for 7 days demonstrated marked peribronchial inﬁltra-
tion of inﬂammatory cells, epithelial hyperplasia, and pronounced
airway eosinophilia. The magnitude of airway eosinophilia in
Rag1/ mice was roughly comparable to that in the wild type
BALB/c mice for up to 5 days; airway eosinophilia further increased
at a later time point in the wild type but not in Rag1/ mice.
Airway eosinophilia on day 5 or day 7 was signiﬁcantly inhibited by
>80% in the ST2/mice as compared to the wild type mice. These
ﬁndings suggested that airway type 2 immune responses to Alter-
naria exposure consist of at least two arms: an initial innate im-
mune response and a subsequent involvement of adaptive
immunity; both arms are IL-33 dependent.
Subsequent studies established that the lung ILC2 population is
the cell type that mediates this rapid type 2 cytokine production
and pathological changes in response to Alternaria allergens.50
In vitro culture of lung cells from naïve mice with IL-33 induced
robust production of IL-5 and IL-13. Importantly, the lung cells that
produced IL-5 did not express authentic markers for T cells (CD3,
CD4, CD8), B cells (B220), macrophages (F4/80), mast cells/baso-
phils (FcεRIa), or granulocytes (Gr-1), but they expressed Thy1.2,
CD25 and CD44. When LinCD25þCD44hi lung cells were cultured
with IL-33, they produced large quantities of IL-5 and IL-13. By FACS
analysis, LinCD25þCD44hi cells highly expressed ST2, CD127
(IL7Ra), Sca-1, CD69, Thy1.2, CD9, CD38, and ICOS, consistent with
published the characteristics of ILC2s.4 The lung ILC2 cell popula-
tion was nearly absent in the lungs of Il7r/ C57BL mice, sug-
gesting a critical role for IL-7 to induce and/or maintain ILC2s.
To directly examine the involvement of ILC2 cells in airway re-
sponses to Alternaria, a reconstitution approach was undertaken.
When ILC2-deﬁcient Il7r/ mice received lung ILC2 cells from a
donor, the ILC2 population was clearly detected in the lungs of the
recipients, suggesting a successful homing (Fig. 2A). Importantly,
Il7r/ mice that were reconstituted with ILC2s and exposed to
Alternaria extracts showed marked increases in eosinophil
numbers and levels of IL-5 and IL-13 proteins (Fig. 2B). Pathologi-
cally, peribronchial inﬁltration of inﬂammatory cells, epithelial
hyperplasia, and increased mucus production were observed in
Il7r/ mice reconstituted with ILC2s and exposed to Alternaria
(Fig. 2C). Together, these results demonstrate the potent capacity of
lung ILC2s in mediating IL-5 and IL-13 production, type-2 airway
inﬂammation and pathological features of asthma upon exposure
to Alternaria even in the absence of adaptive immune cells, such as
T cells and B cells. Furthermore, in another study, a single intranasal
exposure to Alternaria induced rapid production of CysLT that could
activate ILC2s through CysLT1R, suggesting that an IL-33-
independent pathway may also be involved.66 In mice that were
already sensitized to ryegrass allergen, exposure to Alternaria
enhanced proliferation and/or recruitment of both ILC2s and CD4þ
T cells and promoted airway inﬂammation and pathology.72 Theroles of ILC2s in innate type 2 responses were also demonstrated by
mouse models using authentic proteases, such as papain and
bromelain as surrogates of allergen proteases, as well as Aspergillus
proteases.51,73
Chitin is a polysaccharide constituent of fungi. Exposure of naïve
mice to chitin particles induced expression of IL-25, IL-33 and TSLP,
which activated lung ILC2s and induced IL-5 and IL-13 production
and subsequent accumulation of eosinophils and alternatively
activated macrophages.74 In the absence of all three epithelial-
derived cytokines, ILC2s failed to produce IL-5 or IL-13. Interest-
ingly, genetic ablation of ILC2s enhanced IL-1b, TNFa, and IL-23
expression, increased activation of IL-17A-producing gdT cells,
and induced prolonged neutrophilic inﬂammation of the airways.
Thus, chitin-elicited activation of ILC2s may promote type 2 im-
mune response and airway eosinophilia while it may suppress gdT
cell-mediated neutrophilic airway inﬂammation.
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trigger production of epithelium-derived cytokines, such as IL-33.
Allergen could be recognized by the immune system via three
major mechanisms: 1) engagement of pattern recognition re-
ceptors, 2) molecular mimicry of TLR signaling complex molecules,
and 3) proteolytic activity.75,76 In particular, TLR4 likely plays a
critical role in type 2 immune responses to inhaled HDM
allergens,77e79 low-dose LPS in the airways,80 and papain injected
into skin.81 Furthermore, inhaled proteases promoted ﬁbrinogen
cleavage; the ﬁbrinogen cleaved products in turn served as ligands
for TLR4.82 IL-33, IL-25 and TSLP were produced by airway
epithelial cells when they were cultured with Alternaria and pro-
teases in vitro.69,83,84 IL-33 and TSLP were produced quickly in the
lungs of naïve mice exposed to cysteine proteases, such as
bromelain and papain.73 However, mice deﬁcient in TLR4 or a
protease-activated receptor 2 (PAR2) developed comparable levels
of airway eosinophilia compared to WT mice. Importantly, upon
exposure to proteases, uric acid (UA) was rapidly released into the
airway lumen, and removal of this endogenous UA by uricase
prevented type 2 immune responses.73 Conversely, exogenous UA
promoted secretion of IL-33 by airway epithelial cells in vitro, and
administration of UA into the airways of naïve animals induced
extracellular release of IL-33, followed by activation of ILC2s. These
ﬁndings provide mechanistic insights into the development of type
2 immunity to fungi and allergen proteases and suggest that an
endogenous danger signaling molecules, such as UA, may play key
roles in regulating type 2 immune responses in respiratory mucosa.
Clearly, further studies are necessary to elucidate the molecular
mechanisms involved in cytokine production by airway epithelial
cells when they are exposed to allergens.
Role of ILC2s in chronic airway inﬂammation induced by
fungi
ILC2s may interact with other immune cells and play roles in
chronic airway inﬂammation. For example, ILC2 cell numbers were
not maintained in Rag2/ mice infected with helminths or chal-
lenged with the protease papain,39,60 suggesting that adaptive
immune cells (presumably T cells) are required for ILC2 expansion,
migration or survival. Naïve CD4þ T cells supported proliferation
and type 2 cytokine production by ILC2s in an IL-2-dependent
manner.85 Conversely, lung ILC2s enhanced CD4þ T cell prolifera-
tion and promoted production of type 2 cytokines in vitro.86 The
interaction between ILC2s and CD4þ T cells likely involved the
costimulatory molecule OX40L and IL-4, which was mainly derived
from ILC2s. Nonetheless, ILC2-deﬁcient mice effectively produced
Th2 cell-mediated allergic airway inﬂammation in an OVA model,
suggesting that ILC2s may promote the initiation of Th2 cell dif-
ferentiation whereas they do not seem to be required for activation
of established memory Th2 cells.87 ILC2s may also interact with
other immune cells. A more recent study showed that activation
and proliferation of lung ILC2s in mice exposed to the protease
papain were reduced in mice that are deﬁcient in IL-4, speciﬁcally
in the basophil compartment.88 Furthermore, the initial description
of ILC2s in FALC demonstrated that ILC2-derived IL-5 and IL-6 may
promote IgA antibody production by B1 B cells.38 Thus, ILC2s and
their products have the potential to interact with a variety of im-
mune cells, including CD4þ T cells, basophils and B cells, and ILC2s
may need to be considered as a key part of the immune cell
network involved in allergic immune responses.
To investigate the immunological mechanisms in fungus-
mediated chronic airway inﬂammation, mice were exposed to
multiple airborne allergens, including the fungals allergen Alter-
naria and Aspergillus as well as HDM, for a prolonged period.89
Chronic and multiple exposures to these allergens induced arobust increase in BAL eosinophils, which peaked in 4 weeks; eo-
sinophils made up approximately 70% of total BAL cells. Plasma
concentrations of antigen-speciﬁc IgE and IgG1 antibodies
continued to rise for at least 8 weeks. Increased lung levels of type 2
cytokines, including IL-4, IL-5, and IL-13, were also observed.
Notably, a marked increase in the lung levels of IL-33, approxi-
mately 10-times more than a baseline level, was observed in 4
weeks. In this model, unlike the acute exposure models as
described above, increases in BAL eosinophils and cytokines as well
as in plasma IgE were abolished in Rag1/ mice, suggesting a
critical role for adaptive immunity. Nonetheless, the number of
ILC2s increased by>2-fold when animals were exposed to allergens
for 4 weeks, suggesting their potential involvement.
The functions of these ILC2s during chronic inﬂammation were
examinedmore in detail by using cytokine reporter mice, including
the IL-5 reporter IL-5þ/venus mice and IL-13 reporter IL-13þ/eGFP
mice. In PBS-exposed mice, a small fraction of ILC2s expressed IL-5
or IL-13; no other cell populations within the Lin population
expressed these cytokines. Importantly, when mice were exposed
to allergens, both the proportion and absolute number of IL-5- or
IL-13-producing ILC2s increased by approximately 4-fold. Unlike
ILC2s, IL-5 or IL-13 signals were undetectable within the CD3þ cell
population in PBS-exposed animals. When mice were exposed to
allergens, the prevalence of IL-5- or IL-13-positive cells increased
dramatically; these cytokine-positive CD3þ T cells expressed CD4.
The absolute number of type 2 cytokine-positive CD4þ T cells was
approximately 5 times more than that of the cytokine-positive
ILC2s.89 Similarly, during adaptive immune responses in mice
exposed to HDM or OVA, both ILC2s and CD4þ T cells were sources
of IL-5 and IL-13.62,90 Altogether, both ILC2s and CD4þ T cells likely
contribute to the increased IL-5 and IL-13 production in mice after
prolonged airway exposure to airborne allergens. However, the
relative contributions of these cell types still need to be elucidated,
considering that ILC2s might have a greater capacity to produce
type 2 cytokines than CD4þ T cells on a per cell basis.38
Recent studies provide mechanistic insights as to how ILC2s
might regulate adaptive immunity and chronic airway inﬂamma-
tion. For example, adoptive transfer of both ILC2 and CD4þ T cell
populations, but not each population alone, into Il7ra/ mice
resulted in induction of a robust antigen-speciﬁc type 2-cytokine
response and airway inﬂammation when mice were exposed to
protease allergens, suggesting synergistic interactions between
ILC2s and CD4þ T cells during development of adaptive immune
responses.86 In another study, intranasal administration of papain
stimulated both ILC2s and Th2 cells, causing allergic lung inﬂam-
mation and elevated levels of IgE antibodies.91 This process was
severely impaired in ILC2-deﬁcient mice. Indeed, ILC2-derived IL-
13, but not IL-4, was critical as it promoted migration of activated
lung DCs into the draining lymph node where they primed naive T
cells to differentiate into Th2 cells. Importantly, both papain-
induced ILC2 activation and Th2 cell differentiation were depen-
dent on IL-33.
ILC2s and IL-33 also played key roles in the persistence of airway
remodeling and AHR induced by fungal and other allergens.92
Elimination of T cells in mice with allergen-induced chronic
airway inﬂammation resulted in resolution of airway inﬂammation,
but AHR or remodeling continued without T cells. Elimination of
both T cells and ILC2 or blockade of IL-33 resulted in resolution of
airway inﬂammation and AHR. Importantly, epithelial IL-33 acti-
vated ILC2s to produce IL-13, which in turn promoted production of
IL-33 and ST2 expression by airway epithelial cells. Thus, during a
chronic phase of airway inﬂammation, epithelial cells and ILC2s
may form a positive feedback loop, resulting in continued airway
remodeling and AHR even in the absence of antigens or adaptive
immunity.
Fig. 3. Working model to describe the roles of ILC2s in type 2 immune response in the airway exposed to fungal and protease allergens. In the resting condition, IL-33 is stored in
the nucleus of airway epithelial cells. Exposure to fungal or protease allergens induce the extracellular release of IL-33 and production of IL-25 and TSLP by the airway epithelium.
Autocrine secretion of ATP and uric acid likely play a key role in regulating epithelial release of IL-33. IL-33, IL-25 and TSLP activate ILC2s to produce a large quantity of type 2
cytokines, such as IL-5, IL-13, IL-9, and amphiregulin. Basophil-derived IL-4 may facilitate ILC2 production of cytokines. ILC2-derived IL-13 enhances antigen uptake and migration of
dendritic cells and promotes proliferation and differentiation of Th2-type CD4þ T cells. In addition, ILC2s and Th2-type CD4þ T cells may interact directly to sustain production of
type 2 cytokines. Abbreviations: Baso, basophils; DC, dendritic cells; TSLP, thymic stromal lymphopoietin.
H. Kita / Allergology International 64 (2015) 219e226224Finally, corticosteroid resistance is associated with persistent
asthma and poses a major problem in the treatment of patients
with severe asthma. In a mouse model of airway inﬂammation, in
which mice were sensitized with OVA and then challenged with
OVA, treatment with dexamethasone generally attenuated airway
inﬂammation. In contrast, when mice were challenged with OVA
plus IL-33, increased numbers of ILC2s and considerable production
of type 2 cytokines persisted despite dexamethasone treatment.93
These steroid-resistant ILC2s are likely induced by TSLP that is
produced during allergic inﬂammation of the airway and then ac-
tivates STAT5 and Bcl-xL in ILC2s. Altogether, these studies suggest
that involvement of ILC2s in allergic airway inﬂammation is un-
likely to be limited to the innate immune response but extends to
regulation of chronicity and persistence of airway inﬂammation
induced by allergens. The current working model to describe the
roles of ILC2s in fungus- and protease-induced type 2 airway im-
mune responses is provided in Fig. 3.
Concluding remarks
After identiﬁcation and characterization of ILC2s in 2010,38e40
our knowledge of the biology of this novel cell type has expanded
quickly. ILC2s are resident in various normal tissues. Although small
in number, ILC2s likely play major roles in innate immunity and
disease processes by producing large quantities of type 2 cytokines
and tissue growth factors. In mice, ILC2s show both pathological
and protective functions in virus- or allergen-induced allergic im-
mune responses. Furthermore, ILC2s may also work with other
immune cells, such as CD4þ T cells, DCs, and epithelial cells, and
promote development and persistence of allergic airway
inﬂammation.
However, the research in ILC2s is still in its infancy, and many
questions remain to be addressed. For example, ILC2s contribute tothe initiation and persistence of fungus-mediated allergic immune
responses in mice. However, little is known about whether and
how ILC2s are involved in the chronic and recurrent airway
inﬂammation that is observed in human patients with asthma and
other allergic diseases. The increased prevalence of ILC2s in nasal
polyp tissues from patients with chronic rhinosinusitis55,94,95 and
in peripheral blood specimens from patients with asthma96 suggest
that ILC2s are likely involved. At the cellular level, the interactions
between ILC2s and other immune and tissue cells such asmast cells
and epithelial cells, as well the mechanisms involved in these in-
teractions, need to be studied. Our knowledge of the processes
involved in migration and tissue localization of ILC2s is also lacking.
Finally, information is limited regarding themolecular mechanisms
that explain how airway exposure to fungi and other allergens re-
sults in increased production and secretion of pro-type 2 cytokines,
such as IL-33, leading to activation of ILC2s and other inﬂammatory
cells in airwaymucosa. Thus, a further understanding of the biology
of ILC2s, their roles in disease status, and the molecular and cellular
mechanisms involved in the activation and persistence of ILC2s will
help us to better understand the mechanisms of asthma and other
allergic airway diseases and to develop novel therapeutic options
for these diseases.Conﬂict of interest
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